Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance

Journal of Medical Virology

Volumn 84, Issue 3, 2012, Pages 424-430

  Yang, Hyo Joon ^a   Lee, Jeong Hoon ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir resistance; Multidrug resistance; Rescue therapy

Indexed keywords

ADEFOVIR DIPIVOXIL; CREATININE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BRESLOW METHOD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 84862953011     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23229     Document Type: Article

References (30)

1. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao Y-C, Lok AS, Han K-H, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, the BAISG. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-1010.
2. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG. 2005. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129: 1198-1209.
3. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. 2010. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 48: 3641-3647.
4. Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim SO. 2010. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 17: 171-177.
5. Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY. 2009. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 14: 985-993.
6. Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG, Kim YJ, Yoon JH, Lee HS. 2011. Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudine-resistant chronic hepatitis B. Dig Dis Sci 56: 2130-2136.
7. European Association For The Study Of The Liver. 2009. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 50: 227-242.
8. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. 2002. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123: 719-727.
9. Ghany MG, Doo EC. 2009. Antiviral resistance and hepatitis B therapy. Hepatology 49: S174-S184.
10. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. 2010. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 53: 449-454.
11. Hochberger S, Althof D, Gallegos de Schrott R, Nachbaur N, Rock H, Leying H. 2006. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 35: 373-380.
12. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. 2001. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 33: 403-405.
13. Kurashige N, Ohkawa K, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hosui A, Miyagi T, Ishida H, Tatsumi T, Kanto T, Takehara T, Hayashi N. 2009. Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. Antivir Ther 14: 873-877.
14. Lee JM, Park JY, Kim do Y, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH. 2010. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 15: 235-241.
15. Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA. 2008. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: Successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 20: 773-777.
16. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. 2009. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 49: 72-79.
17. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714-1722.
18. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45: 507-539.
19. McMahon BJ. 2005. Epidemiology and natural history of hepatitis B. Semin Liver Dis 25: 3-8.
20. Park NH, Chung YH, Lee HS. 2010. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 53: 20-28.
21. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray DF, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126: 91-101.
22. Qi X, Xiong S, Yang H, Miller M, Delaney WE. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12: 355-362.
23. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45: 307-313.
24. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. 2009. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 50: 674-683.
25. Song BC, Cui XJ, Kim H. 2005. Hepatitis B virus genotypes in Korea: An endemic area of hepatitis B virus infection. Intervirology 48: 133-137.
26. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. 2007. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51: 902-911.
27. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49: 1503-1514.
28. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trepo C, Zoulim F. 2003. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39: 1085-1089.
29. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46: 531-538.
30. Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki F, Kumada H, Chayama K. 2007. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol 79: 1811-1817.